Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.59
NAS:TEAR's Cash-to-Debt is ranked lower than
74% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. NAS:TEAR: 0.59 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:TEAR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: No Debt Max: No Debt
Current: 0.59
Equity-to-Asset -0.22
NAS:TEAR's Equity-to-Asset is ranked lower than
95% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:TEAR: -0.22 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:TEAR' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.59  Med: 0.68 Max: 0.96
Current: -0.22
-1.59
0.96
Piotroski F-Score: 5
Altman Z-Score: -26.86
Beneish M-Score: -4.34
WACC vs ROIC
15.42%
-239.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -57.04
NAS:TEAR's Operating Margin % is ranked lower than
69% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NAS:TEAR: -57.04 )
Ranked among companies with meaningful Operating Margin % only.
NAS:TEAR' s Operating Margin % Range Over the Past 10 Years
Min: -46452.17  Med: -341.61 Max: -57.03
Current: -57.04
-46452.17
-57.03
Net Margin % -71.11
NAS:TEAR's Net Margin % is ranked lower than
70% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NAS:TEAR: -71.11 )
Ranked among companies with meaningful Net Margin % only.
NAS:TEAR' s Net Margin % Range Over the Past 10 Years
Min: -75902.17  Med: -403.82 Max: -71.11
Current: -71.11
-75902.17
-71.11
ROA % -71.95
NAS:TEAR's ROA % is ranked lower than
82% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NAS:TEAR: -71.95 )
Ranked among companies with meaningful ROA % only.
NAS:TEAR' s ROA % Range Over the Past 10 Years
Min: -132.11  Med: -75.36 Max: -37.9
Current: -71.95
-132.11
-37.9
ROC (Joel Greenblatt) % -270.01
NAS:TEAR's ROC (Joel Greenblatt) % is ranked lower than
70% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NAS:TEAR: -270.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:TEAR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7452.46  Med: -3369.34 Max: -270.01
Current: -270.01
-7452.46
-270.01
3-Year Revenue Growth Rate 133.00
NAS:TEAR's 3-Year Revenue Growth Rate is ranked higher than
98% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NAS:TEAR: 133.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:TEAR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.5 Max: 263.5
Current: 133
0
263.5
3-Year EBITDA Growth Rate 72.80
NAS:TEAR's 3-Year EBITDA Growth Rate is ranked higher than
98% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NAS:TEAR: 72.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:TEAR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -77.7  Med: 13.9 Max: 169.6
Current: 72.8
-77.7
169.6
3-Year EPS without NRI Growth Rate 65.90
NAS:TEAR's 3-Year EPS without NRI Growth Rate is ranked higher than
96% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. NAS:TEAR: 65.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:TEAR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -78.6  Med: 20 Max: 135.5
Current: 65.9
-78.6
135.5
GuruFocus has detected 2 Warning Signs with TearLab Corp $NAS:TEAR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:TEAR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TEAR Guru Trades in Q1 2016

Chuck Royce 85,000 sh (unchged)
» More
Q2 2016

TEAR Guru Trades in Q2 2016

Chuck Royce 85,000 sh (unchged)
» More
Q3 2016

TEAR Guru Trades in Q3 2016

Jim Simons 19,800 sh (New)
Chuck Royce 85,000 sh (unchged)
» More
Q4 2016

TEAR Guru Trades in Q4 2016

Jim Simons 38,100 sh (+92.42%)
Chuck Royce 85,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with TEAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:OTCPK:MYAN, OTCPK:MNLIF, NAS:BASI, OTCPK:TBIO, NAS:CBMX, OTCBB:RPBIF, OTCPK:MDIT, OTCPK:EXDI, OTCPK:BZYR, NAS:IDXG, OTCPK:MHTX, NAS:ROKA, OTCPK:LEDIF, OTCPK:DIGP, OTCPK:MTST, NAS:GENE, OTCPK:BTHCF, NAS:ROSG, OTCPK:CRRVF, NAS:BIOP » details
Traded in other countries:TLB.Canada, OCVN.Germany,
Headquarter Location:USA
TearLab Corp is an in-vitro diagnostic company. The Company commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film.

TearLab Corp was incorporated as OccuLogix, Inc. in Delaware in 2002. The Company is an in-vitro diagnostic company based in San Diego, California. The commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. The Company's wholly-owned subsidiary, TearLab Research, Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. The Company's first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor's office. Osmolarity is a quantitative and specific biomarker that has been shown to assist in the diagnosis and disease management of DED. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using an efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. The Company relies on two suppliers based in the United States for the manufacture of the Readers and Pens which are key components of the TearLab Osmolarity System. The Company also relies on a single supplier, MiniFAB (Aust) Pty Ltd. located in Australia, for the manufacture of the test cards which is also a key component of the TearLab Osmolarity System.

Top Ranked Articles about TearLab Corp

TearLab Announces CE Marking for Next-Generation System

SAN DIEGO, March 06, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) today announced that its next-generation in-vitro diagnostics testing platform is in conformity with all the applicable provisions of In Vitro Diagnostic Medical Devices Directive 98/79 EC enabling CE Marking of the device. CE Marking provides clearance in the European Union (EU) and European Free Trade Association (EFTA) member countries.
For the first time, the TearLab next-generation platform offers eye care professionals the ability to assess multiple biomarkers in human tears with a single nanoliter volume tear collection. The lab-on-a-chip platform provides quantitative measurements of tear proteins in a fully automated workflow that is consistent with the current TearLab Osmolarity System which many physicians have incorporated into their practice. This CE Marking provides regulatory clearance for both the device and the initial next-generation test card, capable of measuring both osmolarity and an inflammation biomarker, which together will help identify patients expected to respond to dry eye disease (DED) therapies. “TearLab’s next generation platform represents a breakthrough in providing improved ability to diagnose ocular diseases. With its multiplexing capability, the system will enable us to measure not only osmolarity, but many other proteins and biomarkers in the tear film that reflect ocular surface conditions such as inflammation and allergy,” said Eric Donnenfeld, MD, Clinical Professor of Ophthalmology New York University Medical Center. “We have used the current TearLab Osmolarity System to aid in the identification of DED patients in our practice and look forward to leveraging the capabilities of the new platform to improve our diagnostic accuracy and enhance the level of patient care we can deliver.” Seph Jensen, CEO of TearLab Corporation added, “CE Marking of our next-generation platform is a groundbreaking achievement for TearLab. This platform offers a safe, convenient and quantitative method to diagnose diseases using human tears. This platform will allow us to iterate various disposable tests aimed at diagnosing both eye related and other systemic diseases without the need to replace and develop hardware for each new test.” The Company also announced that it will move to quickly seek CE Marking for a second protein biomarker that will, when combined with osmolarity and the first inflammation biomarker, comprise the initial commercial multiplex test card on the new platform. The Company then plans to build a robust clinical data package and secure valuable feedback from global key opinion leaders in support of a 510(k) submission to the U.S. Food and Drug Administration, which is expected in the third quarter of 2017. To date, TearLab has placed over 5,000 devices worldwide and had more than 8 million tests performed on the TearLab Osmolarity System globally since the commercial launch in 2012. About TearLab Corporation TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.  TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning the market for dry eye patients, the potential success in developing and commercializing the next generation testing system and the TearLab Osmolarity System, the ability to file and secure additional CE Marking and U.S. Food and Drug Administration approval for the next generation commercial test card and testing device. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 9, 2016, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 9, 2016. We do not undertake to update any forward-looking statements except as required by law.
Investor Contact:
The Ruth Group
Lee Roth
Tel: 646-536-7012
[email protected]

Read more...

Ratios

vs
industry
vs
history
PS Ratio 0.12
TEAR's PS Ratio is ranked higher than
99% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. TEAR: 0.12 )
Ranked among companies with meaningful PS Ratio only.
TEAR' s PS Ratio Range Over the Past 10 Years
Min: 0.1  Med: 17.89 Max: 502.01
Current: 0.12
0.1
502.01
EV-to-EBIT -1.67
TEAR's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. TEAR: -1.67 )
Ranked among companies with meaningful EV-to-EBIT only.
TEAR' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.1  Med: -2.3 Max: -0.1
Current: -1.67
-27.1
-0.1
EV-to-EBITDA -2.14
TEAR's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. TEAR: -2.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEAR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.1  Med: -2.8 Max: -0.2
Current: -2.14
-30.1
-0.2
Current Ratio 3.76
TEAR's Current Ratio is ranked higher than
66% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TEAR: 3.76 )
Ranked among companies with meaningful Current Ratio only.
TEAR' s Current Ratio Range Over the Past 10 Years
Min: 0.28  Med: 2 Max: 16.25
Current: 3.76
0.28
16.25
Quick Ratio 3.22
TEAR's Quick Ratio is ranked higher than
66% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. TEAR: 3.22 )
Ranked among companies with meaningful Quick Ratio only.
TEAR' s Quick Ratio Range Over the Past 10 Years
Min: 0.22  Med: 1.8 Max: 15.2
Current: 3.22
0.22
15.2
Days Inventory 103.81
TEAR's Days Inventory is ranked lower than
60% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. TEAR: 103.81 )
Ranked among companies with meaningful Days Inventory only.
TEAR' s Days Inventory Range Over the Past 10 Years
Min: 61.57  Med: 135.98 Max: 219.56
Current: 103.81
61.57
219.56
Days Sales Outstanding 29.69
TEAR's Days Sales Outstanding is ranked higher than
88% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. TEAR: 29.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEAR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.69  Med: 62.63 Max: 1487.77
Current: 29.69
29.69
1487.77
Days Payable 55.05
TEAR's Days Payable is ranked higher than
51% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. TEAR: 55.05 )
Ranked among companies with meaningful Days Payable only.
TEAR' s Days Payable Range Over the Past 10 Years
Min: 28.27  Med: 115.69 Max: 705.37
Current: 55.05
28.27
705.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.20
TEAR's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. TEAR: -17.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEAR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -132.1  Med: -42.6 Max: -5.6
Current: -17.2
-132.1
-5.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.01
TEAR's Price-to-Median-PS-Value is ranked higher than
99% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. TEAR: 0.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEAR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 1 Max: 22.03
Current: 0.01
0.01
22.03
Earnings Yield (Greenblatt) % -60.03
TEAR's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. TEAR: -60.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEAR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -122.61  Med: 0 Max: 0
Current: -60.03
-122.61
0

More Statistics

Revenue (TTM) (Mil) $28.01
EPS (TTM) $ -43.20
Beta2.15
Short Percentage of Float5.35%
52-Week Range $1.85 - 9.10
Shares Outstanding (Mil)5.37

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -2.78
EPS without NRI ($) -2.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TEAR

Headlines

Articles On GuruFocus.com
TearLab Announces CE Marking for Next-Generation System Mar 06 2017 
TearLab Announces 1-for-10 Reverse Split of Common Stock Feb 24 2017 
TearLab Corporation to Report Fourth Quarter and Full-year 2016 Financial Results on March 9, 2017 Feb 21 2017 
TearLab Provides Update on International Market Milestones Feb 13 2017 
TearLab Osmolarity System Receives Mexican Regulatory Approval Jan 25 2017 

More From Other Websites
ETFs with exposure to TearLab Corp. : April 17, 2017 Apr 17 2017
Today's Research Reports on Stocks to Watch: TearLab and HTG Molecular Diagnostics Apr 04 2017
TearLab Corp. :TEAR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
TearLab Corp. :TEAR-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
TearLab reports 4Q loss Mar 09 2017
TearLab Corporation Reports Fourth Quarter and Year End 2016 Financial Results Mar 09 2017
TearLab Announces CE Marking for Next-Generation System Mar 06 2017
TearLab Announces 1-for-10 Reverse Split of Common Stock Feb 24 2017
TearLab Corporation to Report Fourth Quarter and Full-year 2016 Financial Results on March 9, 2017 Feb 21 2017
TearLab Provides Update on International Market Milestones Feb 13 2017
ETFs with exposure to TearLab Corp. : December 9, 2016 Dec 09 2016
ETF’s with exposure to TearLab Corp. : November 10, 2016 Nov 10 2016
TearLab's Co-Promotion With PRN A Positive, But Rodman & Renshaw Isn't Raising Its Estimates Oct 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)